Editas Medicine, INC Form 4 insider transactions

Patrick Thomas Ellinor Ii, a Director of Editas Medicine, Inc., received 103,400 shares of common stock on August 6, 2026.

Linda Burkly, EVP, CHIEF SCIENTIFIC OFFICER of Editas Medicine, Inc., sold 4,928 shares of common stock on July 28, 2026 for $2.67 per share.

Editas Medicine CFO Amy Parison sold 464 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Editas Medicine CEO Gilmore O'Neill sold 15,380 shares of common stock to satisfy tax withholding requirements related to RSU vesting.

Linda Burkly, EVP and Chief Scientific Officer of Editas Medicine, sold 731 shares to cover tax obligations related to RSU vesting.

Editas Medicine's CEO, Gilmore Neil O'Neill, was granted 1,015,200 stock options with an exercise price of $2.54, vesting over four years.

Editas Medicine's SVP and Chief Financial Officer, Amy Parison, was granted 292,856 stock options with an exercise price of $2.54.

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, was granted 292,856 stock options with an exercise price of $2.54.

Editas Medicine's CEO, Gilmore Neil O'Neill, sold 5,394 shares of common stock at a weighted average price of $2.0197 to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's SVP and CFO, Amy Parison, sold 474 shares of common stock at a weighted average price of $2.02 to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's EVP, Chief Scientific Officer, Linda Burkly, sold 749 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 713 shares of common stock at $2.1531 per share to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine CEO Gilmore O'Neill sold 5,603 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's SVP and CFO, Amy Parison, sold 461 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 710 shares of common stock at $2.5961 per share to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's SVP and CFO, Amy Parison, sold 458 shares of common stock at $2.5961 per share to cover tax withholding obligations from RSU vesting.

Editas Medicine's CEO, Gilmore O'Neill, sold 5,592 shares of common stock to cover tax withholding from restricted stock unit vesting, as per a pre-arranged 10b5-1 plan.

Editas Medicine's SVP and CFO, Amy Parison, sold 679 shares of common stock for $2.58 per share to cover tax withholding obligations from restricted stock unit vesting.

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 5,121 shares of common stock at $2.4911 per share to cover tax withholding obligations related to RSU vesting.

Editas Medicine, Inc. director Jessica Hopfield was granted 37,500 stock options with an exercise price of $1.91 per share, vesting fully on June 6, 2026.

Editas Medicine, Inc. Director David Scadden was granted 37,500 stock options with an exercise price of $1.91, vesting fully on June 6, 2026.

Editas Medicine, Inc. Director Elliott M. Levy was granted 37,500 stock options with an exercise price of $1.91, set to vest in full on June 6, 2026.

Editas Medicine, Inc. Director Bernadette Connaughton was granted 37,500 stock options with an exercise price of $1.91 per share, vesting fully on June 6, 2026.

Editas Medicine, Inc. Director Andrew Hirsch was granted 37,500 stock options with an exercise price of $1.91, scheduled to vest in full on June 6, 2026.

Editas Medicine's SVP and Chief Financial Officer, Amy Parison, sold 446 shares of common stock on June 3, 2025, at a weighted average price of $1.724 per share, to satisfy tax withholding obligations related to restricted stock unit vesting.

Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 726 shares of common stock on June 3, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Editas Medicine CEO Gilmore O'Neill sold 15,192 shares of common stock at a weighted average price of $1.7243 to satisfy tax withholding obligations related to the vesting of restricted stock units.

Amy Parison, SVP and CFO of Editas Medicine, reports the grant of a stock option for 34,672 shares on April 8, 2025.

Erick Lucera, EVP and CFO of Editas Medicine, reports the acquisition of stock options in the company.

CEO Gilmore O'Neill received two stock option grants from Editas Medicine on March 8, 2025, according to a Form 4 filing.